Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recent launch event of the Experimental Medicine Industry Partnership was an exciting collaboration between industry representatives and researchers from the University of Oxford. During the event, a series of workshops were held to discuss opportunities, challenges, and future directions for the application of experimental medicine in psychiatric drug development.

Business Unity and connection partnership as ropes shaped as a circle in a group of diverse strings connected together shaped as a support symbol expressing the feeling of teamwork and togetherness.

Dr Susannah Murphy, Department of Psychiatry, University of Oxford, explains:

 

'The Experimental Medicine Industry Partnership (EMIP) is a fantastic opportunity for industry partners and researchers to work together to share expertise and maximise opportunities for developing improved psychiatric treatments. By offering tailored peer review and advice the EMIP will help to rapidly progress new treatments into clinical trials, bringing potential new, life changing treatments a step closer to improving the lives of patients.'

Professor Catherine Harmer, Department of Psychiatry, University of Oxford, said:

 

'It was fascinating to hear pressing questions from an industry perspective and to take part in discussions with other academics. The conversations have spearheaded many collaborations and have inspired us to develop our models in ways that can also work for industry and their requirements. I look forward to continued and future collaborations.'

50 representatives from 15 industry partners and 90 Oxford researchers with expertise in cognitive neuroscience, pharmacology treatment, lifestyle interventions, gut health and precision psychiatry, took part in the AIMday event in July 2021, . 

Read more about this and other topics discussed during the event

For more information about the Experimental Medicine and Industry Partnership (EMIP) 

An Academic Industry Meeting Day (AIMday) is an innovative networking event that allows organisations external to the University of Oxford to set the agenda and gain academic perspective on industry challenges. 

The event was developed through the National Institute for Health Research Oxford Health Biomedical Research Centre (a partnership between the University of Oxford and the Oxford Health NHS Foundation Trust).

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Help-Seeking After Self-Harm in Adolescent Students

A recent survey found that young people who self-harm primarily turn to friends (one in three) and parents (one in four) for support. Formal sources of support, such as Child and Adolescent Mental Health services (CAMHS), psychologists, psychiatrists, or GPs, and online or phone-based services, were accessed by considerably fewer young people.

Ethics at Westminster: A Workshop on Public Values and the Pandemic

At an event organised by the UK Pandemic Ethics Accelerator at the House of Commons on 18 May 2022, parliamentarians, policy makers and academics joined together to discuss how to bring ethical thinking and debate into public policy on pandemic recovery and preparedness, and how to involve the public.

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Anxiety Disorders Among Children, Assessment and Working with Families

Anxiety disorders are the most common mental health disorders among children, yet there is limited guidance on the process of assessing child anxiety disorders and sharing diagnostic outcomes with families.

Landmark New Clinical Trial Shows Benefits of Automated Virtual Reality (VR) Treatment for Severe Psychological Problems

The gameChange automated VR program is designed to treat agoraphobia in patients with psychosis. In the largest ever clinical trial of virtual reality for mental health, gameChange especially helped people whose anxiety had previously left them virtually housebound.